The tender offer period finished with around 92 percent of Beckman Coulter shareholders tendering their shares.
Danaher commenced a subsequent offering period set to expire on June 29, after which it expects to complete its purchase of Beckman Coulter.
The European Commission approved the deal, clearing the way for Danaher to complete the $6.8 billion purchase by the end of the month.
President and CEO J. Robert Hurley is now also interim Diagnostic Division President, while Scott Atkins was named president of the Life Science Division.
The company said that it anticipates regulatory approval from the European Commission on or about June 16 and to close the acquisition by the end of the month.
The company's Clinical Diagnostics segment was up 3 percent year over year, while Life Science slid 11 percent.
The trials will evaluate biomarker panels for lung, colon, and prostate cancer, and may include a comparison of proteomics-based lung cancer tests from Somalogic and Celera.
The deadline for the deal has been pushed back to April 27 from March 23.
In a research note, Jon Groberg wrote that in the near term firms with a larger consumables presence in Japan face greater revenue risk, while instrument firms face greater mid-term risk.
The firms have said they expect to complete the transaction in the first half of this year.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.